CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 558 enrolled
Drug / intervention
ADS-5102, 137 mg +2 moredrug
Likely dose
ADS-5102, 137 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03436199
NCT03436199Phase 3Completed
CompareCT.gov

A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment

Adamas Pharmaceuticals, Inc.·interventional·Posted Feb 19, 2018·Updated Dec 21, 2021

In Brief

A Phase 3 clinical trial evaluating ADS-5102, 137 mg, ADS-5102, 274 mg, and 1 other intervention for Walking Impairment and Multiple Sclerosis. Completed, enrolled 558 participants across 84 sites in 2 countries.

Detailed Summary

This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWalking Impairment, Multiple Sclerosis
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 19, 2018
Enrollment StartMar 29, 2018
Primary CompletionDec 10, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.4 years ago

Interventions

ADS-5102, 137 mgdrug

Oral capsules

ADS-5102, 274 mgdrug

Oral capsules

Placeboother

Oral capsules